{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T07:16:31Z","timestamp":1780384591276,"version":"3.54.1"},"reference-count":57,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2011,9,6]],"date-time":"2011-09-06T00:00:00Z","timestamp":1315267200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0023379","type":"journal-article","created":{"date-parts":[[2011,9,6]],"date-time":"2011-09-06T17:17:39Z","timestamp":1315329459000},"page":"e23379","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":176,"title":["Multicenter Phase 2 Trial of Sirolimus for Tuberous Sclerosis: Kidney Angiomyolipomas and Other Tumors Regress and VEGF- D Levels Decrease"],"prefix":"10.1371","volume":"6","clinical-trial-number":[{"clinical-trial-number":"nct00126672","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Sandra L.","family":"Dabora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Neal","family":"Franz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Ashwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Sagalowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis J.","family":"DiMario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Miles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Cutler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darcy","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul N.","family":"Uppot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahmin","family":"Rabenou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Camposano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Paolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Fennessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsey","family":"Woodrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Manola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Garber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2011,9,6]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMra055323","article-title":"The tuberous sclerosis complex.","volume":"355","author":"PB Crino","year":"2006","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1177\/088307389801301206","article-title":"Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria.","volume":"13","author":"ES Roach","year":"1998","journal-title":"J Child Neurol"},{"key":"ref3","first-page":"1639","article-title":"Loss of tuberin in both subependymal giant cell astrocytomas and angiomyolipomas supports a two-hit model for the pathogenesis of tuberous sclerosis tumors.","volume":"151","author":"EP Henske","year":"1997","journal-title":"Am J Pathol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/nn.2477","article-title":"Tsc2-Rheb signaling regulates EphA-mediated axon guidance.","volume":"13","author":"D Nie","year":"2010","journal-title":"Nat Neurosci"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nm1788","article-title":"Reversal of learning deficits in a Tsc2+\/\u2212 mouse model of tuberous sclerosis.","volume":"14","author":"D Ehninger","year":"2008","journal-title":"Nat Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1086\/316951","article-title":"Mutational Analysis in a Cohort of 224 Tuberous Sclerosis Patients Indicates Increased Severity of TSC2, Compared with TSC1, Disease in Multiple Organs.","volume":"68","author":"SL Dabora","year":"2001","journal-title":"Am J Hum Genet"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1164\/ajrccm.164.4.2011025","article-title":"Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis.","volume":"164","author":"DN Franz","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"ref8","article-title":"The tuberous sclerosis complex. Third Ed. ed","year":"1999"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1101\/gad.901101","article-title":"TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth.","volume":"15","author":"X Gao","year":"2001","journal-title":"Genes Dev"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/ng1494","article-title":"Dysregulation of the TSC-mTOR pathway in human disease.","volume":"37","author":"K Inoki","year":"2005","journal-title":"Nat Genet"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0092-8674(01)00333-6","article-title":"Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size.","volume":"105","author":"CJ Potter","year":"2001","journal-title":"Cell"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.","volume":"356","author":"G Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.","volume":"372","author":"RJ Motzer","year":"2008","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors.","volume":"364","author":"JC Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/gcc.20118","article-title":"Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models.","volume":"42","author":"L Lee","year":"2005","journal-title":"Genes Chromosomes Cancer"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1523\/JNEUROSCI.0955-08.2008","article-title":"Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function.","volume":"28","author":"L Meikle","year":"2008","journal-title":"J Neurosci"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1479-5876-8-14","article-title":"Comparison of three rapamycin dosing schedules in A\/J Tsc2+\/\u2212 mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors.","volume":"8","author":"C Woodrum","year":"2010","journal-title":"Journal of Translational Medicine"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ana.21331","article-title":"Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.","volume":"63","author":"LH Zeng","year":"2008","journal-title":"Ann Neurol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1093\/jnen\/63.12.1236","article-title":"Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.","volume":"63","author":"JA Chan","year":"2004","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S0140-6736(03)13044-9","article-title":"Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma.","volume":"361","author":"N El-Hashemite","year":"2003","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"30958","DOI":"10.1074\/jbc.M202678200","article-title":"Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM).","volume":"277","author":"EA Goncharova","year":"2002","journal-title":"J Biol Chem"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0022-5347(01)63072-6","article-title":"Renal lesion growth in children with tuberous sclerosis complex.","volume":"160","author":"DH Ewalt","year":"1998","journal-title":"J Urol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0025-6196(12)61196-3","article-title":"Causes of death in patients with tuberous sclerosis.","volume":"66","author":"CW Shepherd","year":"1991","journal-title":"Mayo Clin Proc"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1148\/radiol.2252011584","article-title":"Tuberous sclerosis complex: renal imaging findings.","volume":"225","author":"KA Casper","year":"2002","journal-title":"Radiology"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1464-410X.2009.08649.x","article-title":"Angiomyolipomata: challenges, solutions, and future prospects based on over 100 cases treated.","volume":"105","author":"P Sooriakumaran","year":"2009","journal-title":"BJU Int"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials.","volume":"10","author":"R Simon","year":"1989","journal-title":"Controlled Clinical Trials"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.","volume":"92","author":"P Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2165\/00003088-200140080-00002","article-title":"Clinical pharmacokinetics of sirolimus.","volume":"40","author":"K Mahalati","year":"2001","journal-title":"Clinical Pharmacokinetics"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1600-6143.2004.00411.x","article-title":"Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients.","volume":"4","author":"M Schubert","year":"2004","journal-title":"Am J Transplant"},{"key":"ref30","article-title":"Fitting Models to Biological Data using Linear and Nonlinear Regression","author":"H Motulsky","year":"2003"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa063564","article-title":"Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.","volume":"358","author":"JJ Bissler","year":"2008","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/j.transproceed.2009.06.003","article-title":"Sirolimus and everolimus induced pneumonitis in adult renal allograft recipients: experience in a center.","volume":"41","author":"A Rodriguez-Moreno","year":"2009","journal-title":"Transplant Proc"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/sj.ejhg.5201402","article-title":"Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype\u2013phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex.","volume":"13","author":"O Sancak","year":"2005","journal-title":"Eur J Hum Genet"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"591","DOI":"10.4065\/75.6.591","article-title":"High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex.","volume":"75","author":"LC Costello","year":"2000","journal-title":"Mayo Clin Proc"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1164\/ajrccm.164.4.2101154","article-title":"Prevalence and clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex.","volume":"164","author":"J Moss","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ceb.2008.12.012","article-title":"VEGFs and receptors involved in angiogenesis versus lymphangiogenesis.","volume":"21","author":"M Lohela","year":"2009","journal-title":"Curr Opin Cell Biol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1160\/TH03-04-0200","article-title":"Lymphangiogenic growth factors, receptors and therapies.","volume":"90","author":"M Lohela","year":"2003","journal-title":"Thromb Haemost"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"6085","DOI":"10.1073\/pnas.97.11.6085","article-title":"Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis.","volume":"97","author":"T Carsillo","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1378\/chest.08-1160","article-title":"Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement.","volume":"135","author":"CG Glasgow","year":"2009","journal-title":"Chest"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1089\/lrb.2006.4.143","article-title":"Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis.","volume":"4","author":"K Seyama","year":"2006","journal-title":"Lymphat Res Biol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1056\/NEJMc0707517","article-title":"Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis.","volume":"358","author":"LR Young","year":"2008","journal-title":"N Engl J Med"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1378\/chest.10-0573","article-title":"Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases.","volume":"138","author":"LR Young","year":"2010","journal-title":"Chest"},{"key":"ref43","article-title":"Sirolimus Therapy for Angiomyolipoma in Tuberous Sclerosis and Sporadic Lymphangioleiomyomatosis: A Phase 2 trial.","author":"DM Davies","year":"2011","journal-title":"Clin Cancer Res"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.","volume":"363","author":"DA Krueger","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"30958","DOI":"10.1074\/jbc.M202678200","article-title":"Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM).","volume":"277","author":"EA Goncharova","year":"2002","journal-title":"J Biol Chem"},{"key":"ref46","article-title":"Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis.","author":"FX McCormack","year":"2011","journal-title":"N Engl J Med"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1164\/rccm.200911-1720OC","article-title":"Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma.","volume":"182","author":"DA White","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/GIM.0b013e31803068c7","article-title":"Genotype\/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States.","volume":"9","author":"KS Au","year":"2007","journal-title":"Genet Med"},{"key":"ref49","article-title":"Low-dose rapamycin reduces kidney volume angiomyolipomas and prevents the loss of renal function in a patient with tuberous sclerosis complex.","author":"R Peces","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/archdermatol.2010.125","article-title":"Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis.","volume":"146","author":"AK Haemel","year":"2010","journal-title":"Arch Dermatol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1365-2133.2008.08677.x","article-title":"The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis.","volume":"159","author":"GF Hofbauer","year":"2008","journal-title":"Br J Dermatol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-5945-8-1","article-title":"Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model.","volume":"8","author":"A Rauktys","year":"2008","journal-title":"BMC Dermatol"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/gcc.20357","article-title":"Combination of a rapamycin analog (CCI-779) and interferon-gamma is more effective than single agents in treating a mouse model of tuberous sclerosis complex.","volume":"45","author":"L Lee","year":"2006","journal-title":"Genes Chromosomes Cancer"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-2210-9-8","article-title":"Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models.","volume":"9","author":"N Lee","year":"2009","journal-title":"BMC Pharmacol"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/GIM.0b013e31817b80fd","article-title":"Developing a national collaborative study system for rare genetic diseases.","volume":"10","author":"MS Watson","year":"2008","journal-title":"Genet Med"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1164\/ajrccm.160.2.9901027","article-title":"Decline in lung function in lymphangioleiomyomatosis: relation to menopause and progesterone treatment.","volume":"160","author":"SR Johnson","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1378\/chest.126.6.1867","article-title":"Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone.","volume":"126","author":"AM Taveira-DaSilva","year":"2004","journal-title":"Chest"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0023379","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T21:30:10Z","timestamp":1560547810000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0023379"}},"subtitle":[],"editor":[{"given":"Carmine","family":"Zoccali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,9,6]]},"references-count":57,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2011,9,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0023379","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.724172368.793501498","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,6]]}}}